A potential benefit of targeting IL-18 as a therapy in Chagas cardiomyopathy has been proposed based on the observed association between the IL18-607 AA genotype (to which low IL-18 production is associated) and decreased risk of developing cardiomyopathy in Chagas disease patients (Gomes dos Santos et al., 2020). This evidence concerns the gene IL18 and Chagas disease.